Actinium Pharmaceuticals, Inc. — Q3 2014 Form 10-Q
Business context and reporting period. This unaudited filing covers the quarter and nine months ended September 30, 2014. Actinium is a clinical-stage biotechnology company developing targeted cancer therapies, including Actimab-A and Iomab-B. It had no approved products, commercial operations, or revenue.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| R&D expense | $3.77 million | $0.78 million | $8.24 million | $2.37 million |
| General and administrative expense | $3.26 million | $0.83 million | $7.35 million | $2.73 million |
| Net loss | $6.08 million | $1.42 million | $19.26 million | $4.89 million |
| Net loss per share | $0.21 | $0.06 | $0.73 | $0.22 |
| Operating cash used | Not stated separately | Not stated separately | $9.30 million | $4.95 million |
At September 30, 2014, cash and cash equivalents were $11.75 million, current assets $12.42 million, total assets $12.60 million, current liabilities $10.23 million, and stockholders’ equity $2.37 million. Current liabilities included $8.22 million of derivative liabilities, measured using Level 3 inputs; the company reported no note payable outstanding. Nine-month investing cash use was $0.15 million, financing cash provided was $15.67 million, and cash increased $6.22 million. No gross margin or operating margin is meaningful given the absence of revenue.
Material changes versus prior periods
- Nine-month net loss widened by about $14.37 million. Operating expenses rose $10.50 million, while other expense shifted from $0.21 million of income to $3.65 million of expense, primarily from a fair-value loss on derivative liabilities.
- R&D growth reflected Iomab-B/BC8 manufacturing and clinical development, including about $2.4 million of BC8 manufacturing costs in Q3 and about $3.5 million of increased BC8 manufacturing costs for the nine-month period.
- G&A increases reflected higher stock-based compensation, payroll, and professional fees. Nine-month stock-based compensation was $5.22 million, substantially higher than the prior-year period.
- Operating cash use increased, while financing cash inflows rose chiefly through equity issuance. The company completed a public offering and over-allotment in 2014, reporting approximately $13.7 million gross proceeds; it also received proceeds from warrant and option exercises.
Outlook, risks, commitments, and unusual items
- Management said available cash was sufficient to fund operations through the next 12 months, while anticipating continued losses and increasing R&D and G&A spending. This is management’s estimate, not a guarantee.
- Actinium planned to seek FDA authorization in 2014 for a pivotal Iomab-B trial, estimated to cost approximately $25–30 million through anticipated completion in 2016. The company estimated approximately $7 million in direct costs to complete the two parts of the ongoing Actimab-A Phase 1/2 trial.
- Success depends on clinical results and regulatory approval, continued research and commercial collaborations, access to radioactive material and antibodies, manufacturing capability, intellectual-property protection, and additional financing or a favorable partnership.
- Material development commitments include a $3.3 million Goodwin manufacturing agreement, with approximately $2.3 million remaining at quarter-end; an estimated $0.8 million CRO project for Iomab-B; and a September research agreement with Einstein for $183,391. The filing also describes potentially significant milestone and royalty obligations under license agreements.
- Derivative liability valuation is sensitive to the company’s share price and management assumptions. The nine-month $3.65 million fair-value loss was noncash; a $0.97 million fair-value gain was recorded in Q3.
- Subsequent to quarter-end, approximately 386,000 shares were issued in October upon conversion of approximately 485,000 warrants and payment of approximately $18,000. The filing also reports that no Rule 10b5-1 trading plans had been entered into as of October 31, 2014.
- The company reported effective disclosure controls as of September 30, 2014 and no material change in internal control over financial reporting during the quarter. Its cash was held at one U.S. bank and was usually above FDIC-insured limits.
Key facts for investors to verify
- Whether cash runway assumptions remain adequate given the planned Iomab-B trial and continued cash burn.
- The timing, regulatory status, expected design, and funding of the Iomab-B pivotal trial and Actimab-A clinical program.
- Future dilution from outstanding options and warrants: 2.998 million options and 7.934 million warrants were outstanding at September 30, 2014, before the October warrant conversion.
- The assumptions and potential volatility underlying the $8.22 million Level 3 derivative liability and related earnings impact.
- Offering proceeds and net cash amounts: the filing gives differing net-proceeds figures for the 2014 public offering in its narrative; the precise amount is unclear from the filing text and should be reconciled with the detailed offering disclosures.
- The status and remaining cost of manufacturing, trial, license, and royalty commitments, and whether additional capital or partnership funding will be required.